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Background: NOTCH signaling can exert oncogenic or tumor suppressive functions and
can contribute to chemotherapy resistance in cancer. In this study, we aimed to clarify
the clinicopathological significance and the prognostic and predictive value of NOTCH1
and NOTCH2 expression in gastric cancer (GC).
Methods: NOTCH1 and NOTCH2 expression was determined immunohistochemically
in 142 primarily resected GCs using tissue microarrays and in 84 pretherapeutic biopsies
from patients treated by neoadjuvant chemotherapy. The results were correlated with
survival, response to therapy, and clinico-pathological features.
Results: Primarily resected patients with NOTCH1-negative tumors demonstrated worse
survival. High NOTCH1 expression was associated with early-stage tumors and with
significantly increased survival in this subgroup. Higher NOTCH2 expression was associ-
ated with early-stage and intestinal-type tumors and with better survival in the subgroup
of intestinal-type tumors. In pretherapeutic biopsies, higher NOTCH1 and NOTCH2
expression was more frequent in non-responding patients, but these differences were
statistically not significant.
Conclusion: Our findings suggested that, in particular, NOTCH1 expression indicated
good prognosis in GC. The close relationship of high NOTCH1 and NOTCH2 expression
with early tumor stages may indicate a tumor-suppressive role of NOTCH signaling in GC.
The role of NOTCH1 and NOTCH2 in neoadjuvantly treated GC is limited.
Keywords: stomach neoplasms, receptor NOTCH1, receptor NOTCH2, prognosis, chemotherapy, immunohisto-
chemistry
Introduction
The NOTCH signaling cascade is a highly conserved signaling pathway, with a crucial role
in developmental processes and differentiation programs in various tissues. Aberrant NOTCH
signaling has been implicated in carcinogenesis in various organs, and oncogenic, as well as
tumor-suppressive functions, have been described (1, 2). In addition, there has been increasing
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evidence that NOTCH signaling contributes essentially to a drug-
resistant phenotype of tumor cells (3).
There are fourNOTCHreceptors (NOTCH1, 2, 3, 4), which can
transmit activating signals from the cell membrane to the nucleus,
leading then to the transcription of specific target genes (1, 2).
Different and partly opposite roles in one tumor entity have been
found for NOTCH1 and NOTCH2, indicating specific functions
of the two receptors (4).
In gastric cancer (GC), NOTCH1 and NOTCH2 are believed
to contribute to tumor progression (5–7). NOTCH1 has been
reported to be a marker of poor prognosis, and increased expres-
sion of the NOTCH intracellular domain (NICD) was associated
with the presence of lymph node metastasis and worse survival
(8, 9).
In a recent study, we demonstrated the prognostic relevance of
NOTCH2 gene expression in residual tumor cells after chemother-
apy of neoadjuvantly treated GC patients. In addition, an increase
in NOTCH2 expression in the residual tumor cells compared to
the pretherapeutic biopsies was shown, indicating a prominent
role of NOTCH2 in chemotherapy resistance in GC (10).
In this study, we first aimed to clarify the role of NOTCH1
and NOTCH2 protein expression in gastric carcinomas relative
to prognosis and to the clinico-pathological characteristics of
patients not treated by chemotherapy. Second, we aimed to deter-
mine the predictive and prognostic relevance of both proteins for
neoadjuvant chemotherapy, and we included a group of prethera-
peutic tumor biopsies of neoadjuvantly treated GC patients in the
study.
Materials and Methods
Patients and Specimens
Gastric carcinomas from 226 patients operated on in the Depart-
ment of Surgery at the Technische Universität München, Ger-
many, between 1992 and 2010 were analyzed. The study popula-
tion encompassed two subgroups and the patients’ characteristics
are shown in Table 1.
The first subgroup consisted of 142 resected specimens of
patients who had been treated by surgical resection without
neoadjuvant chemotherapy. Follow-up was calculated from the
day of surgery until the last contact with the patient. Patients who
died within 4weeks after surgery were excluded from survival
analysis. Overall survival (OS)was defined from the day of surgery
to death from any cause. Survival data were available for 126 of the
142 patients. The median follow-up time for these patients was
40.1months (range: 0.3–116.1months), and the median OS was
15.8months (95%CI 8.1–23.5months).
The second subgroup encompassed 84 pretherapeutic biopsies
of advanced gastric carcinoma patients (cT3+ cT4 only), who
were treated with a platinum/5FU-based neoadjuvant chemother-
apy, as reported previously (10).
Response to therapy was evaluated histopathologically, as
described previously (11). In brief, all patients with <10% resid-
ual tumor cells per tumor bed [tumor regression grade 1
(TRG1)] were classified as responders. All other patients with
10–50% (TRG2) and with more than 50% residual tumor cells
per tumor bed (TRG3), as well as patients who demonstrated
TABLE 1 | Patient characteristics.
Variable Category Primary resected
tumors
Pretherapeutic
biopsies
n (%) n (%)
Patients 142 (100) 84 (100)
Age (years) Median 70.9 63.4
Range 39.5–99.9 39.2–77.6
Sex Female 55 (39) 23 (27)
Male 87 (61) 61 (73)
Tumor localisationa Proximal 33 (23) 59 (70)
Medial 39 (27) 14 (17)
Distal 54 (38) 10 (12)
Total 12 (8) 1 (1)
Laurén classification Intestinal 76 (54) 28 (33)
Non-intestinal 66 (46) 56 (67)
Tumor grade G1+ 2 26 (18) 9 (11)
G3+ 4 116 (82) 75 (89)
Resection categoryb R0 82 (58) 68 (81)d
R1+ 2 54 (38) 15 (18)d
pT categoryc pT1+ 2 64 (45) 63 (75)d,e
pT3+ 4 78 (55) 20 (24)d,e
pN categoryc pN0 36 (25) 36 (43)d,f
pN1+ 2+ 3 106 (75) 47 (56)d,f
aFor four patients, the tumor localization was unknown.
bFor six patients, the resection category was unknown.
cTNM Classification of Malignant Tumors, 6th Edition, UICC (doi:
10.1371/journal.pone.0044566.t001).
dOne patient with progressive disease was not submitted to surgery.
eCorresponds to ypT.
fCorresponds to ypN.
tumor progression during chemotherapy, were classified as non-
responders. Among the 84 patients, there were 22 (26%) respond-
ing and 62 (74%) non-responding patients.
Follow-up for these patients was calculated from the first day
of chemotherapy until the last contact with the patient. OS was
defined from the first day of chemotherapy until death from
any cause. The median follow-up time for these patients was
40.6months (range: 7.0–84.7months), and the median OS was
50.6months (mean OS 52.8months 95% CI: 50.0–60.7). The
responders had significantly better OS than the non-responders
(plog-rank= 0.041; median OS not reached and 50.6months,
respectively; mean OS 63.9months, 95% CI: 50.0–77.7 versus
44.3months, 95% CI 36.5–52.2, respectively).
The use of the tissue samples was approved by the local ethics
committee of the Faculty of Medicine, Technische Universität
München, Germany (Ref. 4071/11, 21/04/2011) and the informed
consent of the patients was obtained according to the institutional
regulations.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraf-
fin embedded (FFPE) tumor biopsies and on tissue microarrays
(TMAs) of resected specimens. Tissue cores with a diame-
ter of 1.0mm from randomly selected tumor areas were used
for the preparation of the TMAs. The monoclonal NOTCH1
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(bTAN20-s) and NOTCH2 antibodies (C651.6DbHN) were
obtained from the Developmental Studies Hybridoma Bank
(DSHB, the University of Iowa, Department of Biology, Iowa
City, IA, USA) and were used undiluted for NOTCH1 and at a
dilution of 1:30 for NOTCH2. Specificity of the antibodies was
determined by western blotting, using the GC cell line MKN28
with short hairpin RNA-mediated knockdown of NOTCH1 or
NOTCH2 expression, respectively (Figure S1 in Supplementary
Material).
Expression was evaluated by two researchers (AT and RL for
NOTCH2, LB and JSH for NOTCH1). Cytoplasmic and nuclear
staining was determined separately. Negative, weak, medium,
and strong staining intensities were scored as 0, 1, 2, and 3,
respectively. The percentage of tumor cells with stained cyto-
plasm/nucleus was scored as 0 (negative), 1 (<10%), 2 (10 to
<50%), 3 (50 to <80%), or 4 (80%). Multiplication of staining
intensities and percentages resulted in a staining index (SI) rang-
ing from 0 to 12, as described previously (12). We defined an SI of
0 as negative expression, 1–2 as weak, 3–6 as moderate, and 8–12
as strong expression.
Statistical Analysis
Associations between the SIs and qualitative clinical and
histopathological features were tested by the χ2 test or Fisher’s
exact test, depending on the cell counts of the corresponding
contingency tables. Survival was estimated by Kaplan–Meier
curves. The minimal p-value of log-rank tests was used to
dichotomize the patients according to their various expression
groups. Corresponding p-values served as effect measurements to
determine optimality and should not interpreted in a probabilistic
manner. For that purpose, appropriate p-values of maximally
selected log-rank statistics were determined in a permutation
test framework and are indicated as pmax. In multivariate Cox
regression analysis, stepwise forward variable selection was
performed based on likelihood ratio tests. Because our study was
an explorative study, there was no adjustment for multiple testing.
All of the statistical testing was performed using a two-sided
5% significance level. SPSS software (IBM, Armonk, NY, USA),
version 22.0, was used.
Results
Frequency of NOTCH1 and NOTCH2 Expression
in Primarily Resected Gastric Carcinomas
NOTCH1 expression was evaluable in 133 of the 142 primarily
resected tumor specimens. Strong cytoplasmic expression was
found in 10 (8%) of the 133 tumors, 38 (29%) demonstrated
moderate expression, 42 (32%) demonstrated weak expression,
and 43 (32%) were negative.
NOTCH2 expression was evaluable in all of the 142 primarily
resected tumors. Nine tumors (6%) showed strong cytoplasmic
expression, 61 (43%) showed moderate cytoplasmic expression,
53 (37%) showedweak cytoplasmic expression, and 19 (13%)were
negative.
None of the tumors showed nuclear NOTCH1 expression.
Regarding nuclear NOTCH2 expression, 64 (45%) of the 142
tumors were negative, 63 (44%) demonstrated weak expression,
and 15 (11%) tumors showed moderate/strong expression.
The expression frequencies for primary resected tumors are
shown in Figure 1A. Examples of staining patterns are shown in
Figure 2.
Expression of NOTCH1 and NOTCH2 in Primarily
Resected Gastric Carcinomas and Correlation
with Clinico-Pathological Characteristics
Expression was analyzed for an association with the clinico-
pathological characteristics and with the survival of the patients
in the subgroup of 142 primarily resected carcinomas. NOTCH1
was evaluable in 133 of the 142 cases andNOTCH2 in all 142 cases.
Strong NOTCH1 expression was associated with earlier tumor
stages (p= 0.043; pmax= 0.061) (Figure 3A). No significant
association of NOTCH1 expression with histopathological type
according to Laurén, tumor differentiation, lymph node status,
tumor location, or age was found.
Regarding NOTCH2, higher cytoplasmic expression was
significantly associated with intestinal-type tumors (p= 0.004;
pmax= 0.011) (Figure 3B), was more prevalent in lower tumor
stages (pT1+ pT2) (p= 0.030; pmax= 0.081) (Figure 3C) and
was more frequently found in patients with negative lymph node
FIGURE 1 | Distribution of NOTCH1 and NOTCH2 protein expression in
142 primarily resected gastric carcinomas (A) and 84 pretherapeutic
biopsies of neoadjuvantly treated patients (B). Staining indices are grouped
into negative, weak, moderate, and strong expression categories as described
in the Section “Materials and Methods.” The absolute number of cases is
indicated above the bars.
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FIGURE 2 | Staining patterns for NOTCH1 (A–D) and NOTCH2
(E–H) in primary resected GC specimen. NOTCH1: (A) high-intensity
cytoplasmic staining (SI 12), (B) medium-intensity cytoplasmic staining
(SI 4), (C) low-intensity cytoplasmic staining (SI 2), and (D) negative cytoplasmic
staining for NOTCH1 (SI 0); NOTCH2: (E) high-intensity cytoplasmic
staining (SI 9) and low-intensity nuclear staining (SI 1), (F) medium-intensity
cytoplasmic staining (SI 6) and low-intensity nuclear staining (SI 1); (G)
low-intensity cytoplasmic staining (SI 3) and negative nuclear staining (SI 0);
and (H) negative cytoplasmic and nuclear staining for NOTCH2. Scale
bars: 50 µm.
FIGURE 3 | Association of NOTCH1 or NOTCH2 protein expression with
clinico-pathological features of primary resected gastric carcinomas.
Numbers above the bars indicate the absolute number of cases. p-Values were
determined by the χ2-test or Fisher’s exact test; pmax corresponds to p-values
for maximally selected statistics. (A) Cytoplasmic NOTCH1 expression and
association with tumor stage; (B) cytoplasmic NOTCH2 expression and
association with histopathological tumor type; (C) cytoplasmic NOTCH2
expression and association with tumor stage; (D) cytoplasmic NOTCH2
expression and association with lymph node status; (E) nuclear NOTCH2
expression and association with tumor stage.
status (p= 0.044; pmax= 0.065) (Figure 3D). Regarding nuclear
NOTCH2 expression, positive expression (weak/moderate/
strong) was associated with lower tumor stages (pT1+ pT2),
compared to advanced tumor stages (pT3+ pT4) (p= 0.027;
pmax= 0.043) (Figure 3E). No other significant differences were
found.
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Expression of NOTCH1 and NOTCH2 in Primarily
Resected Gastric Carcinomas and Prognosis
Patients who did not show any NOTCH1 expression in their
tumors demonstrated significantly worse survival, compared to
all other patients having weak, moderate, or strong NOTCH1
expression (plog-rank= 0.035; pmax= 0.117) (Figure 4A).
Analyzing the patients with NOTCH1-negative tumors for
an association with survival in the subgroups of (a) early
(pT1+ pT2) and advanced (pT3+ pT4) tumor stages sepa-
rately, (b) in intestinal and non-intestinal-type tumors, and (c)
in completely resected (R0) tumors only, revealed significant
associations with NOTCH1-negative tumors and worse sur-
vival in patients with early tumor stages but not in patients
with advanced tumors (plog-rank= 0.007 and plog-rank= 0.999,
respectively) (Figures 4B,C). A trend toward an association
of these patients with worse survival was observed in non-
intestinal tumors but not in intestinal tumors (plog-rank= 0.055
and plog-rank= 0.449, respectively) (Figures 4D,E). In addition,
patients with NOTCH1-negative tumors showed a significant
decrease in survival in the subgroup of patients with completely
resected tumors (plog-rank= 0.048) (Figure 4F).
Multivariate Cox regression analysis, including NOTCH1
expression and the standard prognostic factors, namely pT, pN,
and R-status, revealed no prognostic relevance for NOTCH1
expression neither in the whole study group nor in the subgroup
of completely resected patients. In the subgroup of patients with
early tumor stages (n= 64), NOTCH1 expression was the second
most important factor (HR: 0.82, 95% CI: 0.67–0.99, p= 0.038)
after lymph node metastasis (HR: 3.35, 95% CI 1.30–8.68,
p= 0.013).
Considering NOTCH2, cytoplasmic or nuclear expression did
not demonstrate an association with survival. Subgroup anal-
yses showed an association of strong cytoplasmic NOTCH2
expression with increased survival in patients with intestinal-
type tumors (plog-rank= 0.043; pmax= 0.060) (Figure 5A). In
addition, moderate/high nuclear NOTCH2 expression was also
significantly associated with better survival in this subgroup
(plog-rang= 0.039; pmax= 0.020) (Figure 5B). Multivariate anal-
ysis in intestinal tumors indicated R-status (HR: 2.78, 95%
CI: 1.39–5.55, p= 0.004) and tumor stage (HR: 2.61, 95% CI:
1.28–5.30, p= 0.008) as independent prognostic factor but not
NOTCH2 expression.
Frequency of NOTCH1 and NOTCH2 Expression
in Pretherapeutic Biopsies of Neoadjuvantly
Treated Patients
Expression of NOTCH1 was evaluable in 75 of 84 pretherapeutic
biopsies of patients treated with a neoadjuvant chemotherapy.
FIGURE 4 | Kaplan–Meier survival curves for NOTCH1 protein
expression in primary resected gastric carcinomas. (A) All tumors
(median OS: 15.1months; 95% CI 8.3–22.0 versus 23.3months; 95% CI
4.6–26.1); (B) subgroup of early-stage tumors (pT1+ 2) (median OS:
28.0months; 95% CI 16.2–40.0 versus median OS not reached); (C) subgroup
of advanced-stage tumors (pT3+4) (median OS: 10.3months; 95% CI 0–21.8
versus 8.7months; 95% CI 3.1–14.3); (D) subgroup of non-intestinal-type
tumors (median OS: 12.2months; 95% CI 4.1–20.2 versus 33.2months; 95%
CI not applicable); (E) subgroup of intestinal-type tumors (median OS:
23.1months; 95% CI 12.0–34.2 versus 23.3months; 95% CI 3.0–43.6);
(F) subgroup of patients with completely resected tumors (R0) (median OS:
28.8months; 95% CI 27.1–30.5 versus median OS not reached); p-values were
determined by log-rank statistics; pmax. corresponds to p-values for maximally
selected statistics.
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FIGURE 5 | Kaplan–Meier survival curves for NOTCH2 protein
expression in primary resected gastric carcinomas of the intestinal
type. (A) Cytoplasmic expression (median OS: not reached versus
21.2months; 95% CI 11.4–31.3) and (B) nuclear expression (median OS: not
reached versus 21.4months; 95% CI 11.6–31.1). p-Values were determined
by log-rank statistics; pmax corresponds to p-value for maximally selected
statistics.
Thirteen (17%) of the 75 samples were negative for NOTCH1
protein expression, 26 (35%) showed a weak cytoplasmic
expression, 31 (41%) showed a moderate expression, and 5 (7%)
demonstrated a strong cytoplasmic NOTCH1 expression. None of
the samples showed nuclear NOTCH1 expression.
NOTCH2 was evaluable in 78 of the 84 samples. Cytoplamic
NOTCH2 expression was strong in 4 (5%), moderate in 26 (33%),
weak in 29 (37%), and negative in 19 (24%) of these samples.
Nuclear NOTCH2 expressionwas observed to be strong in 2 (3%),
moderate in 27 (35%), weak in 33 (42%), and negative in 16
(21%) of pretherapeutic biopsies. The expression frequencies for
pretherapeutic biopsies are shown in Figure 1B.
TABLE 2 |NOTCH1 andNOTCH2 protein expression in pretherapeutic tumor
biopsies and response to neoadjuvant chemotherapy.
NOTCH1 NOTCH2
n
SIa<4
n
SI4
p-valueb n
SI<3
n
SI3
p-valueb
Responders 18 1 0.056 19 2 0.079
Non-responders 41 15 40 17
Total 59 16 59 19
aStaining index.
bFisher’s exact test.
Expression of NOTCH1 and NOTCH2 in
Pretherapeutic Biopsies and Response to
Therapy
No association of NOTCH1 or NOTCH2 expression with
response was found using the classification system of negative
(SI 0), weak (SI 1–2), moderate (SI 3–6), and strong (SI 8–12)
expression. Searching for an optimal cut-off value to differentiate
responding and non-responding patients revealed a trend toward
an association of tumors with higher cytoplasmic NOTCH1
(SI 6) or NOTCH2 (SI 4) expression with worse response
(p= 0.056 and p= 0.079, respectively) (Table 2). No significant
associations with survival were found.
Discussion
In this study, we addressed the potential clinical impact of
NOTCH1 andNOTCH2 expression in GC by analyzing both pro-
teins in a group of patients treated directly by primary resection
of their tumors and in another group treated with platinum/5FU-
based neoadjuvant chemotherapy.
One of the most interesting results of our study was the finding
of higher expression of cytoplasmic NOTCH1 and of cytoplas-
mic and nuclear NOTCH2 in early tumor stages (pT1+ pT2),
compared to advanced stages (pT3+ pT4). This finding indicated
that a decrease in expression of both proteins occurred during
tumor progression, suggesting a tumor-suppressive function of
NOTCH signaling in gastric carcinogenesis. Furthermore, our
study showed the prognostic relevance of NOTCH1, with higher
expression being associated with increased survival and no lymph
node metastasis. Beyond this, an impressive prognostic role for
NOTCH1 was found for patients with T1/T2 tumors but not for
patients with advanced pT3/pT4 tumors. Patients with higher
NOTCH1-expressing tumors in the subgroup with early patho-
logical tumor stages had significantly better survival than those
with a low expression, and multivariate analysis indicated that
NOTCH1 expressionwas an independent prognostic factor in this
subgroup. This finding characterized NOTCH1 expression as a
prognostic factor, particularly during early tumor development,
and it additionally supported a possible tumor-suppressive role for
NOTCH signaling.
It is well known that NOTCH signaling can exert oncogenic or
tumor-suppressive functions and that individual NOTCH recep-
tors can exert opposite functions in context- and time-dependent
manners, even in the same tumor type (2). For example, a
tumor-suppressive function has been reported for skin and
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liver cancers, an oncogenic role for NSCLC (2, 13) and a dual
role in the same tumor type for colorectal and pancreatic cancers
(4, 14). The findings of our study ascribed a tumor-suppressive
role to NOTCH signaling in GC. This result was essentially in
agreement with a functional analysis of NOTCH2 in a GC cell
line, which demonstrated that downregulation of NOTCH2 by
siRNA enhanced tumor cell invasion (15). However, our results
were in contrast to findings from other studies mainly performed
in Asian countries, which have reported a contribution of higher
expression of NOTCH1 or NOTCH2 to tumor progression and,
in particular, an association of higher expression of NOTCH1
with worse prognosis (5, 7–9, 16). Furthermore, higher NOTCH2
expression was more frequently found in intestinal-type tumors
in our study, again inconsistently with an analysis of Asian
patients reporting no associations of NOTCH2 expression with
histopathological type (6). The reasons for these discrepancies
are not clear, but they could be related to differences in the
study populations, in the analytical technologies or in the applied
scoring methods. In addition, differences related to the specificity
of the antibodies might exist. In this context, we would like to
emphasize that we demonstrated the specificity of the antibod-
ies that we used in our study by western blotting. In addition,
based on the results in the respective NOTCH1- and NOTCH2-
knockdown cells, we showed that cross-reaction of both antibod-
ies was very unlikely. Interestingly, we observed positive nuclear
staining only for NOTCH2 and not for NOTCH1. This finding
might reflect varying degradation rates of nuclear NOTCH1 and
NOTCH2 proteins or variations in the sensitivities of the specific
antibodies.
In the subgroup of neoadjuvantly treated GC patients, we iden-
tified only a trend toward an association of a higher NOTCH1
andNOTCH2 expression in the pretherapeutic biopsies andworse
tumor regression after chemotherapy. Recent studies have indi-
cated an association betweenNOTCH1 orNOTCH3 and cisplatin
resistance in squamous head and neck and ovarian carcinomas
and in EBV-associated naso-pharynx carcinomas, respectively
(17–19).
We are aware that our study had limitations, mainly related
to its retrospective nature and to the limited number of tumors
we analyzed. Thus, further studies are needed to delineate in
greater detail the role of NOTCH1 and NOTCH2 expression
in gastric carcinogenesis and the impact of these molecules in
the prediction of response to neoadjuvant chemotherapy in GC.
Furthermore, functional analyses are needed to clarify a possible
tumor-suppressive role of NOTCH signaling in GC.
Nevertheless, in conclusion and to the best of our knowledge,
our study showed for the first time a close relationship of a
decrease of NOTCH1 and NOTCH2 expression with tumor pro-
gression in GC, and our findings suggested that, in particular,
NOTCH1 expression was a marker for good prognosis. These
findings taken together may suggest a tumor-suppressive role of
the NOTCH signaling pathway in GC.
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